Background-It has been suggested that phospholipase A2 (PLA2) has an essential role in the pathogenesis of inflammatory bowel diseases. 
Phospholipase A2 (PLA2) is a lipolytic enzyme that catalyses the hydrolysis of the fatty acyl ester bond at the sn-2 position of glycerophospholipids. It is of great interest with regard to the pathogenesis of inflammation as it is the rate limiting enzyme in the synthesis of eicosanoids and, therefore, considered an important regulator of the inflammatory reaction. In addition, the reaction products of PLA2 (lysophospholipids and non-esterified fatty acids) are cytotoxic substances.' Secretory PLA2s are divided into group I and II enzymes (PLA2-I and PIA2-II). PLA2-I is secreted by the exocrine pancreas and serves mainly as a digestive enzyme. PLA2-II has been found by immunohistochemistry in numerous cell types including those of the human gastrointestinal tract.2 3 There is evidence indicating an important role for PLA2-II in the pathogenesis of diseases involving inflammation such as infections, sepsis, arthritides, Crohn's disease, and ulcerative colitis. 4 5 Increased serum concentrations of PLA2-II are found in various inflammatory diseases"7 including inflammatory bowel diseases. 8 Minami and coworkers found increased PLA2-II tissue contents and PLA2 activity in colonic mucosa of patients with ulcerative colitis and Crohn's disease. 9 The studies referred to above give a reason to assume that PLA2-II might be expressed in the inflamed colonic mucosa of patients with ulcerative colitis. However, PIA2-II mRNA was found in the Paneth cells of histologically normal small intestinal mucosa only, whereas no PLA2-II mRNA was detected in samples from normal colonic mucosa by in situ hybridisation.'0
The purpose of this study was to investigate the expression of PLA2-II in tissue samples from the colon and mesenteric lymph nodes of patients with ulcerative colitis. In particular, our aim was to identify cells responsible for the synthesis of P[A2-II in colonic mucosa.
Methods
Samples from the colon, ileum, and mesenteric lymph nodes of six consecutive patients operated on for ulcerative colitis (panproctocolectomy) were studied by light microscopy, PLA2-II immunohistochemistry, and in situ hybridisation and northern hybridisation for PLA2-II mRNA. We also analysed samples from skeletal muscle (the straight muscle of abdomen) and subcutaneous fat in three of these patients. Furthermore, we analysed biopsy specimens from the colonic mucosa (three samples per patient) of six patients with ulcerative colitis undergoing routine colonoscopies. These specimens were studied by the same methods as mentioned above except northern hybridisation. Haapamdki, Grdnroos, Nurmi, Alanen, Kallajoki, Nevalainen Tissue samples were obtained from the colon, ileum and mesenteric lymph nodes during the operation immediately after the resection of the intestine. Samples containing a mucosal area of 20X30 mm and the whole underlying intestinal wall were taken from the most inflamed site of the colonic mucosa, a zone of mild inflammation, and from a macroscopically normal (or closest to normal) part of the colon. Three to four samples of colon and one sample of ileum were taken from each patient at operation. Additional tissue samples were taken from the mesentery and mesenteric lymph nodes (found by inspection and palpation in five out of six cases) close to the inflamed part of the colon. Small muscle and subcutaneous fat samples were taken from the edge of the laparotomy wound. A part of each tissue sample was frozen and stored at -70°C until analysed (pieces of intestinal mucosa, size 5 X 10 mm, lymph nodes, and mesenteric fat for northern blot analysis). The 
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- treatment at the time of the operation or the colonoscopy, respectively (Table) . In addition, seven out of the 12 patients received 5-aminosalicylic acid (patients 1, 4, 5, 6, 8, 10, and 12), and three patients received salazosulfapyridine (patients 2, 9, and 11). The average length of disease history of the patients with ulcerative colitis (n= 12, eight men and four women) was 11 years (range 10 months-29 years) and the mean age of the patients was 39 years (range 23-58 years). Six patients served as controls. Three control patients were operated on for cancer of the colon and three patients underwent diagnostic colonoscopy for mild abdominal symptoms. The colon of these three colonoscopy patients was considered normal. The control samples from the cancer patients were obtained from the resection line of the colon at a distance of at least 30 cm from the site of cancer. In two cases the samples were taken distal and in one case proximal to the site of cancer. There were no signs of intestinal obstruction or any other signs or symptoms of acute disease before the operation. All the control samples were obtained from macroscopically normal colonic mucosa, and were studied by light microscopy, PILA2-II immunohistochemistry, and in situ hybridisation and northern hybridisation for PLA2-II mRNA.
IMMUNOHISTOCHEMISTRY
Sections of formalin fixed paraffin wax embedded tissues were reacted with an IgG fraction of a polyclonal rabbit anti-PLA2-II antiserum.'2 Dewaxed and rehydrated sections were digested with pepsin, (4 mg/ml of 10 mM HCl). The primary antibody was used at a concentration of 0-45 ,ug/ml. The sections were incubated for 18 hours at +4°C. The primary immunoreaction was localised'3 with a commercial biotin-avidin based detection system (Vectastain ABC kit; Vector Laboratories, Burlingame, CA, USA) according to the manufacturer's instructions. For controls, the primary antibody was replaced by preimmune rabbit serum. The sections were counterstained with haematoxylin. IN The hybridisation cocktail contained RNA probes at a concentration of 107 cpm/ml. Other modifications to the previous protocol'0 were the addition of an RNase digestion step and a seven day exposure time of the autoradiographic emulsion. RNase digestion was carried out after hot washes for 30 minutes at 37°C. RNase (Sigma Chemicals, St Louis, MO, USA) was dissolved at a concentration of 20 ,ug/ml in 0 5 M NaCl, 1 mM EDTA, and 10 mM TRIS-HCI, pH 7-5. After autoradiography, the slides were stained with haematoxylin. NORTHERN Mild inflammatory changes were seen in the tissue samples from the ileum in five out of six panproctocolectomy patients. The mesenteric (n=6), skeletal muscle (n=3), and subcutaneous fat samples (n=3) showed no signs of inflammation. The histological structure in the tissue samples from the colon of six control patients appeared normal by light microscopy. IMMUNOHISTOCHEMISTRY PLA2-II was detected by immunohistochemistry in metaplastic Paneth cells of inflamed colonic mucosa in all six patients who had active ulcerative colitis, and in four out of six patients with inactive ulcerative colitis (Table) . The Paneth cells were located mainly in the bottom of the mucosal crypts and gave an intense immunohistochemical reaction for PLA2-LPLA2-II was found by immunohistochemistry also in the columnar epithelial cells of the inflamed colonic mucosa in four out of six patients with active ulcerative colitis and in one out of six patients with inactive disease (Table) . The distribution and number of positive Paneth and columnar epithelial cells seemed to be related to the degree of inflammation in the respective region of the colon. Positive cells were found in any inflamed region of the colon. The immunohistochemical staining intensity of the columnar epithelial cells varied widely. The active ulcerative colitis and in columnar epithelial cells in four out of six patients with active ulcerative colitis (Table) . The distribution of the PLA2-II mRNA positive cells in the colonic mucosa was very similar to the distribution of immunohistochemically positive cells as described in the previous section. The intensity of the in situ hybridisation signal seemed to be related to the degree of inflammation and not to any specific region of the colon. Figures 2 and 3 illustrate positive findings in Paneth cells and columnar epithelial cells. PLA2-II mRNA was detected by in situ hybridisation in the Paneth cells of the ileal mucosa in all patients studied (n=6). In addition, PLA2-II mRNA was detected in the epithelial cells of ileum in one out of six patients. The tissue samples from the mesentery (n=6) including lymph nodes contained no PLA2-II mRNA, and the same negative result was found in samples from skeletal muscle (n=3) and subcutaneous fat (n=3) studied by in situ hybridisation. There were no metaplastic Paneth cells in the colonic mucosa of control patients. We noted a weak positive signal in the columnar epithelial cells in two out of six control patients studied by in situ hybridisation (Table) . (Fig 5) . Two control samples were excluded from the northern blot analysis because of disintegration of the RNA in these samples. The mRNA detected in the positive samples was 0-9 kb in size, as expected for PLA2-II mRNA.10
The samples from the mesentery and mesenteric lymph nodes of five panproctocolectomy patients showed no detectable PIA2-II mRNA as studied by northern hybridisation. In the current study, we found PLA2-II mRNA in the colonic mucosa in all patients with active ulcerative colitis. In addition to the expected positive finding in metaplastic Paneth cells, we found PLA2-II mRNA in the epithelium of inflamed colonic mucosa in four out of six patients with active disease. We also noticed that mesenteric tissue (including mesenteric lymph nodes), skeletal muscle, and subcutaneous fat were devoid of PLA2-II mRNA. All samples were studied by immunohistochemistry for PLA2-II enzyme protein and by in situ hybridisation for PLA2-II mRNA, and additionally, an adjacent part of the same tissue samples was studied by northern hybridisation. Results of the current northern analysis must be interpreted with considerable caution because of unequal loading of RNA into the hybridisation gels. Nevertheless, in the current study, we could differentiate positive samples from negative ones and we found that the detected mRNA was 09 kb in size as expected for PIA2-II mRNA.'0
The current results indicate that both metaplastic Paneth cells and columnar epithelial cells of colonic mucosa synthesise PLA2-II at the site of inflammation in patients with active ulcerative colitis. Paneth cells seem to be the main source of PLA2-II as illustrated in the current study at both enzyme protein and mRNA levels. The activation of the synthesis of PLA2-II seems to take place in concert with the increasing inflammatory activity of colonic mucosa in ulcerative colitis, which supports the view that PLA2-II may play a part in the pathogenesis of ulcerative colitis. So far we cannot define the specific role of PLA2-II in the inflamed colonic mucosa in ulcerative colitis. However, there is room for speculation.
Activation of PLA2-II synthesis may cause harmful effects on the mucosa by generating free radicals or causing release of lysosomal enzymes.2' 22 On the other hand, PIA2-II might protect the mucosa against invasion of pathogenic microbes or play an immunodefensive part mediated by chemotaxis.23 25 Immunoreactive PLA2-II has been found in the brush border of the luminal surface epithelium of the duodenum.2 In the current study, we detected PIA2-II immunoreactivity in the luminal border of colonic epithelial cells in one out of six cases with active ulcerative colitis. These findings support the idea of intraluminal secretion of PLA2-II. It is feasible to postulate that secretion of PLA2-II into the lumen of the gut might be a host defence mechanism during the active phase of ulcerative colitis.
